Recent Updates
Recently added Catalysts

Nelarabine /m2

Phase 1

Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic | Small molecule | Oncology |GSK plc|Last Updated: Nov 13, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
ACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment13
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00406757Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or LymphomaPHASE1 COMPLETED 13Aug 30, 2006Jul 15, 2009Nov 13, 20173 Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Adverse events, changes from baseline in physical examination and clinical laboratory parameters12-lead ECGAssessment of pharmacokinetic endpoints of 506U78, ara-G and intracellular ara-GTP concentration.
Day 21
Secondary Endpoints
Evaluation of response (e.g., CR, CR*) in patients with bone marrow involvement.
Day 21
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Pediatric Arm 1ACTIVE_COMPARATORCycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose. Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
Pediatric Arm 2ACTIVE_COMPARATORCycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
Adult Arm 1ACTIVE_COMPARATORCycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose. Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
Adult Arm 2ACTIVE_COMPARATORCycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
Pediatric Arm 3ACTIVE_COMPARATORNelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
Interventions
NameTypeDescription
Nelarabine injection 400mg/m2DRUGCycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5. Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5.
Nelarabine injection 650mg/m2DRUGNelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
Nelarabine injection 1000mg/m2DRUGCycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5. Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
Nelarabine injection 1500mg/m2DRUGNelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
Unlock Study Design Details
Eligibility Criteria
Age RangeN/A — 64 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Histologic or cytogenetic documented diagnosis of T-ALL or T-LBL. * Disease that is refractory to at least one prior chemotherapy regimen, or has relapsed following complete remission to at least one prior chemotherapy regimen. * At least 4 weeks since the last dose of prior l...

Countries:Japan
Unlock Eligibility Criteria